The Janus face of chlorogenic acid on vascular reactivity: A study on rat isolated vessels
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | The Janus face of chlorogenic acid on vascular reactivity: A study on rat isolated vessels |
Type de publication | Journal Article |
Year of Publication | 2016 |
Auteurs | Tom ENgo Lemba, Girard-Thernier C, Demougeot C |
Journal | PHYTOMEDICINE |
Volume | 23 |
Pagination | 1037-1042 |
Date Published | SEP 15 |
Type of Article | Article |
ISSN | 0944-7113 |
Mots-clés | Chlorogenic acid, Endothelial pathways, Toxicity, Vasorelaxation |
Résumé | Background: Chlorogenic acid (CGA), the main polyphenol contained in coffee, is a major contributor to dietary polyphenol intake. Few studies reported its anti-hypertensive properties but the mechanisms are still indefinite. Purpose: The present study assessed the direct effect of CGA in endothelium denuded or intact aortic rings from male Wistar rats and the mechanisms involved. Methods/Results: CGA induced a direct endothelium-dependent relaxation that was significantly reduced by L-NAME (10(-4) M), indomethacin (10(-5) M) and combination of apamin (10(-7) M) and charybdotoxin (10(-7) M). Incubation of rings with CGA induced a dual effect on agonist-induced vasorelaxation. At 10(-6) M, it enhanced the relaxant effects of acetylcholine and reduced the contracting effects of phenylephrine due to increased basal and stimulated NOS activity, respectively. At 10(-4) M, CGA blunted acetylcholine and bradykinin-induced vasorelaxation, reduced phenylephrine-induced vasoconstriction but did not change the response to sodium nitroprusside, a NO-donor. Conclusion: In summary, CGA induces a direct endothelium-dependent vasodilation by increasing NOS, COX and EDHF signalling pathways. However, this new pharmacological action that can explain some positive effects of CGA in case of hypertension has to be modulated at the light of its deleterious impact on vascular relaxation at high concentrations and incite to be cautious when using high doses of CGA in clinical studies. (C) 2016 Elsevier GmbH. All rights reserved. |
DOI | 10.1016/j.phymed.2016.06.012 |